These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 10825037)

  • 81. Systemic meningococcal disease: a model infection to study acute endotoxinemia in man.
    Brandtzaeg P; Kierulf P; Gaustad P; Dobloug J; Mollnes TE; Sirnes K
    Prog Clin Biol Res; 1988; 272():263-71. PubMed ID: 3393567
    [TBL] [Abstract][Full Text] [Related]  

  • 82.
    Brusletto BS; Hellerud BC; Øvstebø R; Brandtzaeg P
    Front Cell Infect Microbiol; 2023; 13():1298360. PubMed ID: 38089821
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Fibrinolyte therapy of septicemic shock in infancy and childhood].
    Mitterstieler G; Kurz R; Waltl H; Berger H
    Padiatr Padol; 1973; 8(2):225-31. PubMed ID: 4698436
    [No Abstract]   [Full Text] [Related]  

  • 84. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score.
    Kornelisse RF; Hazelzet JA; Hop WC; Spanjaard L; Suur MH; van der Voort E; de Groot R
    Clin Infect Dis; 1997 Sep; 25(3):640-6. PubMed ID: 9314453
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock.
    Fijnvandraat K; Peters M; Derkx B; van Deventer S; ten Cate JW
    Prog Clin Biol Res; 1994; 388():247-54. PubMed ID: 7831362
    [No Abstract]   [Full Text] [Related]  

  • 86. [Monoclonal antibodies in the treatment of septic shock].
    Trilla A; Alonso P
    Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950
    [No Abstract]   [Full Text] [Related]  

  • 87. [Current clinical and therapeutic aspects of meningococcal infections].
    Mingrino F; Ortali V; Rossi F
    Recenti Prog Med; 1971 Sep; 51(3):250-60. PubMed ID: 5003344
    [No Abstract]   [Full Text] [Related]  

  • 88. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock.
    Derkx B; Marchant A; Goldman M; Bijlmer R; van Deventer S
    J Infect Dis; 1995 Jan; 171(1):229-32. PubMed ID: 7798670
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Mechanisms of acute pulmonary edema during meningococcal shock in children (author's transl)].
    Kahn A; Brachet E; Blum D
    Sem Hop; 1981 Dec 8-15; 57(45-46):1925-9. PubMed ID: 6275530
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Monoclonal antibodies in the treatment of sepsis and septic shock].
    Torrabadella de Reynoso P; Salgado Remigio A; Peracaula Picart R
    Med Clin (Barc); 1992 Dec; 99(20):784-92. PubMed ID: 1460952
    [No Abstract]   [Full Text] [Related]  

  • 91. Anti-endotoxin monoclonal antibodies.
    Rosenfeld S
    N Engl J Med; 1992 Sep; 327(12):889; author reply 890-1. PubMed ID: 1508254
    [No Abstract]   [Full Text] [Related]  

  • 92. Neisseria meningitidis: clinical aspects.
    Cartwright KA; Ala'Aldeen DA
    J Infect; 1997 Jan; 34(1):15-9. PubMed ID: 9120319
    [No Abstract]   [Full Text] [Related]  

  • 93. [Naloxone and endotoxic shock: a wonder drug?].
    Valdivielso A; Casado Flores J; Ruiz Beltrán A; García Pérez J; García-Onieva M; Hidalgo I
    An Esp Pediatr; 1984 Feb; 20(2):85-90. PubMed ID: 6712029
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.
    Brandtzaeg P; Kierulf P; Gaustad P; Skulberg A; Bruun JN; Halvorsen S; Sørensen E
    J Infect Dis; 1989 Feb; 159(2):195-204. PubMed ID: 2492587
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Is it possible to treat infections with non-antimicrobial agents?].
    Gómez J; Ruiz-Gómez J; Herrero F
    Enferm Infecc Microbiol Clin; 1993 Dec; 11(10):519-21. PubMed ID: 8142499
    [No Abstract]   [Full Text] [Related]  

  • 96. Early filtration and mortality in meningococcal septic shock?
    Pearson G; Khandelwal PC; Naqvi N
    Arch Dis Child; 2000 Dec; 83(6):508-9. PubMed ID: 11087288
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock.
    Gibaldi M
    Pharmacotherapy; 1993; 13(4):302-8. PubMed ID: 8361858
    [No Abstract]   [Full Text] [Related]  

  • 98. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins.
    Baldwin G; Alpert G; Caputo GL; Baskin M; Parsonnet J; Gillis ZA; Thompson C; Siber GR; Fleisher GR
    J Infect Dis; 1991 Sep; 164(3):542-9. PubMed ID: 1908001
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Naloxone hydrochloride in the therapy of endotoxic shock following meningococcal disease. Initial results].
    Martinón JM; Franco A; García JL; Fuster M; Bao A; Martinón F; Peña J
    An Esp Pediatr; 1982 Dec; 17(6):457-60. PubMed ID: 7183216
    [No Abstract]   [Full Text] [Related]  

  • 100. Management of meningococcal infections.
    Klein NJ; Heyderman RS; Levin M
    Br J Hosp Med; 1993 Jun 16-Jul 13; 50(1):42-9. PubMed ID: 8364705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.